QQQ   347.96 (-0.58%)
AAPL   178.57 (+0.72%)
MSFT   329.68 (-0.46%)
META   262.61 (+0.03%)
GOOGL   123.18 (-0.40%)
AMZN   119.89 (-1.45%)
TSLA   199.65 (-0.75%)
NVDA   383.46 (-4.40%)
NIO   7.41 (+0.00%)
BABA   79.53 (+1.09%)
AMD   119.19 (-4.85%)
T   15.76 (+0.77%)
F   12.01 (-4.61%)
MU   68.48 (-4.48%)
CGC   0.82 (-3.58%)
GE   100.94 (-1.43%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.00 (+2.67%)
PYPL   62.03 (-0.03%)
NFLX   394.56 (+0.40%)
QQQ   347.96 (-0.58%)
AAPL   178.57 (+0.72%)
MSFT   329.68 (-0.46%)
META   262.61 (+0.03%)
GOOGL   123.18 (-0.40%)
AMZN   119.89 (-1.45%)
TSLA   199.65 (-0.75%)
NVDA   383.46 (-4.40%)
NIO   7.41 (+0.00%)
BABA   79.53 (+1.09%)
AMD   119.19 (-4.85%)
T   15.76 (+0.77%)
F   12.01 (-4.61%)
MU   68.48 (-4.48%)
CGC   0.82 (-3.58%)
GE   100.94 (-1.43%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.00 (+2.67%)
PYPL   62.03 (-0.03%)
NFLX   394.56 (+0.40%)
QQQ   347.96 (-0.58%)
AAPL   178.57 (+0.72%)
MSFT   329.68 (-0.46%)
META   262.61 (+0.03%)
GOOGL   123.18 (-0.40%)
AMZN   119.89 (-1.45%)
TSLA   199.65 (-0.75%)
NVDA   383.46 (-4.40%)
NIO   7.41 (+0.00%)
BABA   79.53 (+1.09%)
AMD   119.19 (-4.85%)
T   15.76 (+0.77%)
F   12.01 (-4.61%)
MU   68.48 (-4.48%)
CGC   0.82 (-3.58%)
GE   100.94 (-1.43%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.00 (+2.67%)
PYPL   62.03 (-0.03%)
NFLX   394.56 (+0.40%)
QQQ   347.96 (-0.58%)
AAPL   178.57 (+0.72%)
MSFT   329.68 (-0.46%)
META   262.61 (+0.03%)
GOOGL   123.18 (-0.40%)
AMZN   119.89 (-1.45%)
TSLA   199.65 (-0.75%)
NVDA   383.46 (-4.40%)
NIO   7.41 (+0.00%)
BABA   79.53 (+1.09%)
AMD   119.19 (-4.85%)
T   15.76 (+0.77%)
F   12.01 (-4.61%)
MU   68.48 (-4.48%)
CGC   0.82 (-3.58%)
GE   100.94 (-1.43%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.00 (+2.67%)
PYPL   62.03 (-0.03%)
NFLX   394.56 (+0.40%)
NASDAQ:AXSM

Axsome Therapeutics (AXSM) Stock Forecast, Price & News

$73.18
+3.73 (+5.37%)
(As of 03:21 PM ET)
Compare
Today's Range
$69.45
$73.34
50-Day Range
$58.41
$80.22
52-Week Range
$20.63
$82.85
Volume
432,534 shs
Average Volume
885,723 shs
Market Capitalization
$3.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$105.57

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
45.0% Upside
$105.57 Price Target
Short Interest
Bearish
21.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.34mentions of Axsome Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.84) to ($1.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

299th out of 1,006 stocks

Pharmaceutical Preparations Industry

138th out of 492 stocks


AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
Axsome Therapeutics (NASDAQ: AXSM)
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
Axsome: Promising Early Launch
3 Growth Stocks to Buy and Hold
Q1 2023 Axsome Therapeutics Inc Earnings Call
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings
5/08/2023
Today
5/31/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$105.57
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$52.00
Forecasted Upside/Downside
+46.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

Net Income
$-187,130,000.00
Net Margins
-109.75%
Pretax Margin
-107.97%

Debt

Sales & Book Value

Annual Sales
$50.04 million
Book Value
$2.57 per share

Miscellaneous

Free Float
32,898,000
Market Cap
$3.14 billion
Optionable
Optionable
Beta
1.90

Key Executives

  • Herriott Tabuteau
    Chairman & Chief Executive Officer
  • Mark L. Jacobson
    Chief Operating Officer
  • Nick PizzieNick Pizzie
    Chief Financial Officer
  • Lori Englebert
    Executive VP-Commercial & Business Development
  • Kevin Laliberte
    Executive Vice President-Product Strategy













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2023?

13 Wall Street analysts have issued 12-month price targets for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $52.00 to $200.00. On average, they predict the company's share price to reach $105.57 in the next year. This suggests a possible upside of 52.0% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2023?

Axsome Therapeutics' stock was trading at $77.13 at the beginning of the year. Since then, AXSM stock has decreased by 10.0% and is now trading at $69.45.
View the best growth stocks for 2023 here
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.91. The company had revenue of $94.58 million for the quarter, compared to analysts' expectations of $26.87 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 152.04% and a negative net margin of 109.75%.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (8.68%), BlackRock Inc. (5.67%), BVF Inc. IL (4.89%), FMR LLC (3.13%), State Street Corp (1.83%) and Geode Capital Management LLC (1.50%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $69.45.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.03 billion and generates $50.04 million in revenue each year. The company earns $-187,130,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 108 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -